We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Shares have already been flipped from 43p to 59p. Should move up to 60p fairly quickly if the results are positive. That will form the new base. Something a bit extra and no telling what this could do.
Worth considering that the placing was marketed in the US (hence the 40 blackout period). I would absolutely love to see mention of a US listing. Pave the way for much higher valuations seen over 10x UK.
At 50 pence I suspect a lot of the shares will be flipped.
Not convinced. Axa framlington has shown up on investor holding pages. None others. No TR1s.
‘A number of high quality institutional investors’
Third patient was dosed in the US on 20 March. Second dose would have been 3 April. Two week observation period would have finished on 17 April in the US. We are now 8+ days in the UK on from that, 30 April will be 12+ days. We'd better hear by the time of the interims that Q2W C1 has completed beacause if we don't it would mean either there was a problem with one of the patients or they're not serious about scheduling the SDMC meetings to facilitate the quickest running of this trial.
Btw Timster, if you are going by the 21 March RNS, Avacta made a basic mistake: "the Safety Data Monitoring Committee ("SMDC")". Obviously no one proof reads their blurb before releasing.
Anyone got any thoughts on what the CEO can now discuss once the 40 day blackout has passed?
In a break from tradition, Doris has bought a packet of Ginger Nuts instead of the usual Hobnobs. Expect to hear significantly fewer expletives on Tuesday as the Team manipulate these superior dunkers.
Almost at the end of this mysterious 40 day blackout where the CEO hasn't been allowed to give away any information about the fundraise. The SP was at £1.35 when he told us Avacta was at the beginning of the value curve. Share price is 63 percent down.
What he said.
Thanks for the advice Spartacus, but I’ll pass on your suggestion . I know it’s a cliche but people really should do their own research. Do NOT follow anyone’s suggestions on trades nor on who to follow into a trade for that matter, as it’s pretty much guaranteed they won’t have your best interests in mind (me included).
'those approached for funding support who will have studied all availability Data'. I repeat: We have video evidence that the funds taking part in the placing only cared about one thing and that was the depth of the discount. They were clueless. He had no idea in any detail what was going on. Your generic statements don't apply when clout chaser Paul Hill caught one of them on candid camera.
I don't get in volved with the two and throwing arguments
and the correct gramer it requires to not leave your self open to constant cheap shots any more
I've been hear since a pound what a blody ride
Not sold shares when I should off to maximise position
Hay ho its always been like that learning slowly for 10+ years
I will say this, and you can pull it to bits as easy as you want
But That post there by Windy or though I don't ever completely agree with how he words things
You can normaly take plenty from his post
And if youve got any sense and want too
long term invest/trade you'll let him have his say
I'd rather sit in a room and discuss deabate Avacta with Windy
Than trying to protect the newbies from being put off by what he says occasionally
You can't help new investors....they have to learn the hard way with Time, any other serious Avacta followers read the board every day...and the rinse and repeat repetitive crap
Attacks
I don't need to be constantly told whos right and whos wrong, if I get a tool on hear that talks too his self I'll block him I don't need any one too sensor any body for me thank you
I will be looking under the bed for more at this price
Couldnt realy give a hoot if it goes to 40p or below in the short term, don't think it will unless....
But if Avacta does ever reach any where near any of its possible potential
Then ill of seriously have dropped my average
Windy is watching the price constantly and cleverly/bravely
And I would guess making more money than alot of you
Yes he's dropped massive wallopers for sure if you haven't I am not realy talking too you
I bet you'd be surprised how he recovers
No he's not my mate kids x
As always DYOR
and sorry for the dyslexia
Winne you’ve lrearnt a lot a being on here every minute of the day. Muppet
No disrespect but you can work that out without overly analysing the situation!!
Did you manage to top up?
Don't need crayons and a ruler to work that out!
CH a close above 49p would be a step towards confirming a reversal would be forming. a close above 58p would be much stronger.
Fingers crossed.
My luck is so bad I’m gonna shirt this for a laugh.
Should be 60p by close then 🤪
And what do the charts say if this closes at 50p?
What is your position now mate? Did you hold out for 41p or was you lucky enough to get todays uptick?
Told you previously Windy on FDA approvel this will surpass the ATH, that’s an extremely viable assumption
To make. Doesn’t matter how long you have owned the stock you will still make profit if that happens. Of course you can try trade this, however what’s the point if you believe FDA approval will happen, you could try be smart one day for example the people selling this morning thinking because GSA have increased the short this would tank today but the price today is 9% up or you can just wait it out and not worry. Depends if you want to gamble or believe in the science and overall investment case. The Trial is not a fantasy, it will eventually conclude one way or another. Just a waiting game.
"Again I’m not looking at a week by week share chart, that’s just gambling. I’m looking at the overall trend of where this is heading as an investment opportunity back to a more reasonable valuation, not a quick trade. Although still awaiting that FDA approval catalyst that’s the real prize imo."
well, week by week,... hmmm... 3 years ago it was 250p.
So gambling is simply defined by the amount of time you hold a stock? Thats crap, right...
Although as you say it hinges on FDA approval, which is due very soon? so doesn't it make more sense to invest (not gamble) as short a time as possible before FDA approval is granted?
You may or may not be right about AVCT long term success, who knows, what I don't understand is your blind refusal to ever acknowledge that any development in this long torturous SP slide has been anything other than seemingly expected and a confirmation that everything has gone to plan.
It always comes across as one-eyed, blind faith rather than ever any objective assessment. (Which as an investment strategy is extremely dangerous.)
News could also be from Dr Simon Bennett the Chief Business Officer bringing his 26 years' commercial experience in the biopharma industry (so hopefully more competent than todays RNS authors). Simon has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 (soon to be 81?) commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America. 🤝GLA
Somethings cooking! Is it frying shorters?
Whilst Avacta blockbuster assets IP potential value still to be reflected in current market cap /SP does not mean will not happen , indeed very encouraging progress being made . Plus possibility of affimers being tested in patients later this year with AffyXel JV.
--
"The global stem cell market size was valued at USD 19.41 billion in 2023, driven by the rising prevalence of various non-communicable diseases, the increasing investments in stem cell therapies, and the growing utilization of human-induced pluripotent stem cells (iPSCs). The market is anticipated to grow at a CAGR of 10.3% during the forecast period of 2024-2032 to achieve a value of USD 46.91 billion by 2032."
https://www.expertmarketresearch.com/reports/stem-cell-market
--------------------
Posted earlier 2024
Seng-Ho JeonSeng-Ho Jeon
Former CEO & President of Daewoong pharmaceuticalFormer CEO & President of Daewoong pharmaceutical
https://www.linkedin.com/feed/update/urn:li:activity:7148957324089380864/
AffyXell is a pre-clinical stage biotechnology company with a proprietary platform engine to develop novel cell and gene therapy (CGT). This platform is a powerhouse not only for internal pipelines but also for external collaboration. We have multiple discussions and collaborative studies with external parties to maximize the potential strength and expandability of AffyXell’s platform technologies.
We are dedicated to developing off-the-shelf allogenic cell therapies for the treatment of transplantation rejection and immune disorders. Our technology enables the merge of two different platform technologies from our parent companies: Daewoong's Mesenchymal Stem Cell technology (DW-MSC) and Avacta's Affimer technology.
Our lead pipeline candidate, AFX001, is designed to inhibit CD40-CD40L signaling by binding to CD40L and blocking the interaction through the secretion of an anti-CD40L antagonistic Affimer. CD40-CD40L signaling plays a pivotal role in T cell activation, T cell-mediated B cell activation/differentiation, and immune responses involving antigen-presenting cells (APCs). Inhibition of T cell and B cell activation through CD40-CD40L signaling suppression offers therapeutic potential for conditions like GvHD and various autoimmune diseases, including systemic lupus erythematosus, type 1 diabetes mellitus, multiple sclerosis, and rheumatoid arthritis.
Excitingly, we have demonstrated AFX001's outstanding efficacy compared to un-transduced MSCs using a humanized Graft versus Host Disease (GvHD) mouse model. Furthermore, AFX001 exhibits comparable efficacy to a pre-clinically verified anti-CD40L antibody.
We recently concluded a smooth pre-IND meeting with the US FDA, and we are on track to initiate patient-targeted clinical trials in the second half of this year. We are ready to manufacture GMP batch for the clinical trials with the established GMP-grade Master Cell Bank (MCB) and Working Cell Bank (WCB). " etc
Looks like we could really pop soon.
Rapid rise to 100p+ please